Small diameter polycaprolactone vascular grafts are patent in sheep carotid bypass but require antithrombotic therapy

Shu Fang, Alexander Høgsted Ahlmann, Louise Langhorn, Kamal Hussein, Jens Ahm Sørensen, Xiaowei Guan, Søren Paludan Sheikh, Lars Peter Riber, Ditte Caroline Andersen*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Background: Polycaprolactone (PCL) scaffolds exhibit high biocompatibility and are attractive as vascular conduits. Materials & methods: PCL tubes were cultivated in bioreactor with human adipose regenerative cells to assess ex vivo cytocompatibility, whereas in vivo PCL tube patency was evaluated in sheep carotid bypass with and without antithrombotic treatment. Results: Ex vivo results revealed increasing adipose regenerative cells on PCL using dynamic bioreactor culturing. In vivo data showed that 67% (2/3) of grafts in the antithrombotic group were patent at day 28, while 100% (3/3) of control grafts were occluded already during the first week due to thrombosis. Histology showed that patent PCL grafts were recellularized by host cells. Conclusion: PCL tubes may work as small diameter vascular scaffolds under antithrombotic treatment.

Original languageEnglish
JournalRegenerative Medicine
Volume16
Issue number2
Pages (from-to)117-130
ISSN1746-0751
DOIs
Publication statusPublished - Feb 2021

Bibliographical note

Publisher Copyright:
© 2021

Keywords

  • Biodegradable
  • Polycaprolactone
  • Sheep carotid bypass model
  • Small diameter artery
  • TEVGs
  • Tissue engineered vascular grafts

Fingerprint

Dive into the research topics of 'Small diameter polycaprolactone vascular grafts are patent in sheep carotid bypass but require antithrombotic therapy'. Together they form a unique fingerprint.

Cite this